Table 1.
Patient and disease characteristics (N = 176)
| Patient characteristic | No | Percent of cohort |
|---|---|---|
| Age | ||
| < 60 | 125 | 71.0 |
| ≥ 60 | 51 | 29.0 |
| Sex | ||
| Male | 159 | 90.3 |
| Female | 17 | 9.7 |
| Number of lesions | ||
| Single | 25 | 14.2 |
| Multiple | 151 | 85.8 |
| Number of treatment lines | ||
| 1 | 153 | 86.9 |
| 2 | 20 | 11.4 |
| ≥ 3 | 3 | 1.7 |
| Immunotherapy | ||
| Camrelizumab | 103 | 58.5 |
| Tislelizumab | 44 | 25.0 |
| Sintilimab | 20 | 11.4 |
| Pembrolizumab | 9 | 5.1 |
| ECOG PS | ||
| 0 | 106 | 60.2 |
| ≥ 1 | 70 | 39.8 |
| BCLC stage | ||
| A | 1 | 0.6 |
| B | 34 | 19.3 |
| C | 141 | 80.1 |
| Child–Pugh score | ||
| A | 132 | 75.0 |
| B | 43 | 24.4 |
| C | 1 | 0.6 |
| HBV infection | ||
| No | 17 | 9.7 |
| Yes | 159 | 90.3 |
| Antiviral therapy before treatment | ||
| No | 34 | 19.3 |
| Yes | 142 | 80.7 |
| Liver metastasis | ||
| No | 49 | 27.8 |
| Yes | 127 | 72.2 |
| Lung metastasis | ||
| No | 135 | 76.7 |
| Yes | 41 | 23.3 |
| Lymph node metastasis | ||
| No | 118 | 67.0 |
| Yes | 58 | 33.0 |
| Extrahepatic metastasis | ||
| No | 89 | 50.6 |
| Yes | 87 | 49.4 |
| PVTT | ||
| No | 86 | 48.9 |
| Yes | 90 | 51.1 |
| Ascites | ||
| No | 123 | 69.9 |
| Yes | 53 | 30.1 |
| NLR | ||
| < 3 | 96 | 54.5 |
| ≥ 3 | 80 | 45.5 |
| HGB | ||
| ≥ 120 g/L | 116 | 65.9 |
| < 120 g/L | 60 | 34.1 |
ECOG PS Eastern Cooperative Oncology Group performance status, BCLC Barcelona Clinic Liver Cancer, HBV Hepatitis B virus, PVTT Portal vein tumour thrombus, NLR neutrophil to lymphocyte ratio, HGB haemoglobin